

Cancer Drug Discovery & Preclinical Development

Optimising early-stage research for oncology therapeutics

17th & 18th September 2014

London, United Kingdom

Innovation and investment have led to huge progress in cancer research but discovery of drug candidates must be backed by a comprehensive preclinical strategy and effective allocation of resources. This event will showcase the latest technological advances in cancer drug design and explore the pathway that leads up to clinical trials.

- Review the latest research into targeted anti-cancer therapies
- Explore options for effective use Of next generation sequencing technology
- Hear the latest ideas for epigenetic drug discovery in oncology
- Discuss strategies to achieve a more personalised approach to drug discovery
- Network with industry associates and get direct access to key opinion leaders



Cancer Drug Discovery & Preclinical Development

London, United Kingdom

17th & 18th
September
2014

ACI's Cancer Drug Discovery & Preclinical Development conference will provide you with fresh insights into the early stages of cancer drug development, with a strong focus on new ideas for target identification and validation as well as regulatory strategy and safety assessment. The programme features a diverse range of academic and industry experts to ensure fair and balanced coverage of the latest developments in the field.

Key Areas of Focus:

- Strategies for the identification of selective kinase inhibitors
- New therapeutic targets in epigenetics and newly described metabolic pathways
- Engineering antibodies for targeted cancer therapy
- Ways of ensuring safe and effective use of next generation sequencing technology
- Overcoming mechanisms of drug resistance with new targeted anti-cancer therapies
- Methods for establishing pharmacologically safe and effective dose in animal studies

Event Format:

The two day conference will comprise a series of informative presentations and panel discussions from senior industry executives, academic experts and public sector professionals. This takes place in an environment set up to promote information exchange between you and your peers and opportunities to meet new clients

Who Should Attend?

Heads of Oncology, Research & Development Directors, Heads of Drug Development, Chief Scientific Officers, Drug Discovery Managers, Medicinal Chemists, Formulation scientists, Preclinical Development Scientists, Geneticists, Data Analysts as well as anyone involved in early-stage cancer drug development

Host City of London



Opportunities to Meet Your Target Audience:



Are you interested in promoting your company's drug design-related services to the industry and engaging with potential clients? If so, your company can have an increased level of visibility and exposure through branding and networking as a conference sponsor. This will allow you to attract new business and forge commercial relationships.

For information on available sponsorship and commercial opportunities, please contact: **Victor Kinlock** Tel: +44 (0) 20 3141 0626
Email: vkinklock@acieu.net



Speaking Opportunities:

If you would like to be considered as a speaker for the event with a 30-45 minute presentation, please submit an abstract for consideration to:

Ciaran Larkin
Senior Conference Producer, ACI
Tel: +44 (0)20 3141 0625
Email: clarkin@acieu.net

Registration:

If you would like to register for this event or find out about discounts for multiple bookings contact:

Rohan Baryah
Marketing Manager, ACI
Tel: +48 (0) 616 467 022
Email: rbaryah@acieu.net

DAY ONE

Wednesday 17th September 2014

08:00	REGISTRATION & COFFEE
09:00	CHAIRMAN'S OPENING REMARKS
09:10	OPENING ADDRESS Successfully Building and Prosecuting Industry-Academia Alliances in Oncology - Why we need alliances to further oncology discovery - Alliance models - Running a successful alliance Tim Hammonds Deputy Director of Discovery Cancer Research Technology
09:40	SESSION 1: TARGETING CANCER WITH KINASE INHIBITORS Small Molecule Kinase Inhibitors in Oncology: Current State of the Art & Future Directions - The FDA approval of the kinase inhibitor Imatinib for CML 2001 was landmark and has revolutionised way we treat cancer - This talk will recap on how the field has evolved and cover topics such as targets, inhibitor types, selectivity, tolerability, efficacy and resistance in the - Future directions in the field will be speculated upon based on research being published now David Walker Drug Discovery Program Manager Sentinel Oncology
10:10	CASE STUDY: Discovery of a Novel Inhibitor of mTOR Pathway in Clinical Development - Phenotypic screening of small molecules - In silico tools to unravel de mechanism of action - Multitarget strategy to overcome resistance in tumour cells José Alfón Vice President, Research and Development Ability Pharmaceuticals
11:00	MORNING REFRESHMENTS
11:30	Identification of Selective DUB Inhibitors Targeting DDR Deficient Tumours - DNA damage response (DDR) and synthetic lethality - Ubiquitin proteasome pathways and Deubiquitylating enzymes - Small molecule drug discovery for oncology Xavier Jacq Head of Biology MISSION Therapeutics

12:00	CASE STUDY: A Novel RNA Oligonucleotide that Improves Liver Function & Inhibits Liver Carcinogenesis In Vivo Nagy Habib Chairman and Co-Founder MiNA Therapeutics
12:40	NETWORKING LUNCH
14:00	SESSION 2: CANCER DRUG DISCOVERY TECHNOLOGIES Cancer Drug Targets - Novel Therapeutic Strategies - Antibody drug conjugates as cancer therapeutics - Prodrug activation by hypoxic cancer cells - Discovery of improved platinum analogues - Moving from cytotoxic and cytostatic drugs to cancer cell-specific drugs - Apoptosis and cancer therapeutics - Carbon-14 Labelling of Biomolecules: Antibody Drug Conjugates and Peptides Sean Kitson Investigator of Radiochemistry Almac Group
14:30	Screening & Sequencing Technologies - DNA-directed assembly microarray for protein and small molecule inhibitor screening - Avoiding liabilities through safe and effective use of next generation sequencing technology - Cell-based assay and screening technologies - High content and image-based screening - Innovations in Phenotypic Screening - Fragment screening approaches to targeting invasion and metastasis - Function-based screening for therapeutic cancer targets - Target identification in paediatric tumours Graham Smith Team Leader, PET Radiochemistry The Institute for Cancer Research
15:10	AFTERNOON REFRESHMENTS
15:40	SESSION 3: TACKLING DRUG RESISTANCE & REDUCING FAILURE RATES Drug Resistance & Attrition - Failure modes in anticancer drug discovery - Rapid onset of resistance as a consideration in new drug design - Difference between targeting biological pathway and tumour itself - Overcoming mechanisms of drug resistance in cancer cells with new targeted anticancer therapies Steven Whittaker Team Leader, Career Development Faculty The Institute for Cancer Research

16:10 **Acquired Resistance to Targeted Kinase Inhibitors: Causes, Consequences & Some Solutions**

- Development of potent and selective kinase inhibitors that take advantage of a tumour cell's addiction to specific oncogenic protein kinases
- Cases where clinical responses are not durable and tumours develop acquired resistance leading to relapse
- Mechanisms underpinning acquired resistance and how they provide insights into key control points
- Recent studies of acquired resistance to allosteric MEK1/2 inhibitors and new, ATP-competitive mTOR

Simon Cook
Group Leader, Signalling Laboratory
The Babraham Institute

16:40 AFTERNOON DISCUSSION

17:00 CLOSE OF DAY ONE

DAY TWO

Thursday 18th September 2014

08:00 REGISTRATION & COFFEE

09:00 CHAIRMAN'S OPENING REMARKS

09:10 SPECIAL ADDRESS
Improving the Efficiency and Effectiveness of Cancer Drug Discovery

- Developing novel multi-dimensional methods for molecular similarity comparison
- High-throughput virtual screening of massive cheminformatics databases
- Development of computational methods to support phenotypic screening
- The development of cloud computing paradigms for molecular modelling research

Paul Finn
Professorial Research Fellow
University of Buckingham

09:40 SESSION 4: TRANSLATING EARLY STAGE CANCER RESEARCH
Translational Pharmacology in Oncology: From Discovery to First in Human

- Discovery – model relevance to pathology
- Establishing biomarker – relevance to pathology and therapeutic effect
- Modelling efforts to understand exposure-effect (PK-PD) relationship
- Therapeutic window – predicting clinical Success and cutting your losses early enough

Chandrasekhar Natarajan
Chief Scientific Officer
ViNa Pharma

10:30 MORNING REFRESHMENTS

11:00 Using Preclinical Data to Inform Clinical Dose & Schedule in Oncology: Integrating Predictive Pharmacokinetics, Pharmacodynamics, Efficacy & Safety

- Current approach to formulating translational PK/PD relationships
- Use of preclinical safety understandings to predict minimal clinical effects
- Integrating PK/PD and predictive safety to define optimal starting dose and schedule

Gary Wilkinson
Project Leader, DMPK
AstraZeneca

11:30 Applying Virtual Tumour Technology

- Computer modelling of the growing tumour
- Modelling anti-cancer drug combinations and
- Using the computer to optimise regimens
- Translating from pre-clinical to clinical: challenges and successes

Eric Fernandez
Project Leader
Physiomics

12:20 NETWORKING LUNCH

SESSION 5: PRECLINICAL CHALLENGES
Using Multi-Scale Modeling to Support Preclinical Developments

- How In vitro cellular responses to EGFR inhibitors are different from in vivo responses due to differences in micro-environments
- How a multi-scale model integrates drug-induced cellular responses with micro-environments, and can be used to anticipate clinical settings
- How multi-scale modeling integrates cellular responses with cell-cell interactions
- Guiding schedule designs for preclinical efficacy and safety studies, and anticipating clinical outcomes

Tao You
Systems Biologist
AstraZeneca

14:30 The Value of Preclinical Models for Drug Discovery & Translating Combination Approaches into Early Clinical Trials

- CRUK preclinical model network: from PDX and GEMM through to organoids and ex vivo models
- ECMC Combination Alliance: collaborations with pharma to drive novel combinations
- Drug discovery: maximising information from preclinical models

Hazel Jones
Head of Combination Therapies
Cancer Research UK

15:00 AFTERNOON REFRESHMENTS

SESSION 6: PRODUCT STRATEGY

15:20

The Importance of Observational Data Early on in Cancer Drug Discovery

- Electronic medical records and availability of real world cancer data through registries and networks
- Examples of effective academic- NHS-industry partnerships
- Allocation of resources at beginning of drug discovery process

Aliki Taylor

Observational Research Director
Amgen

15:50

From the Laboratory to the Market Place

- Getting more investment in technology, resources, and time
- State of play in industry-academia partnerships
- Making your own luck by acting on seemingly disparate data
- The role of patent lawyers and accountants in drug design
- IP support strategy and competitive intelligence
- Epidemiological assessment

Angela Kukula

Director of Enterprise
The Institute for Cancer Research

16:20

Planning for Success – IP Considerations

- Protecting early stage IP
- IP strategies for collaborations, including considerations on IP ownership, IP access and freedom to operate

Mike Nelson

Partner
HGF Limited

16:50

AFTERNOON DISCUSSION

17:10

CLOSE OF CONFERENCE

Registration Is Simple

If you would like to register for this event or wish to find out more information, you can contact Cheryl Williams using any of the following methods:

 +48 (0) 616 467 022

 rbaryah@acieu.net

 <http://www.acieu.net>

 **Postal Address:**
ACI Europe, 5/13 Great Suffolk Street, London, SE1 0NS

Registration Is Simple

Conference (Includes Documentation Packet)

17-18 September 2014

£1,495 (ex. VAT)

Documentation Packet Only

£420 (inc. P&P)

Please Note.

Members and customers of all supporting organisations are entitled to a discount off their conference package.

For more information please call +48 (0) 616 467 022

Documentation Packet Available

We are selling the Cancer Drug Discovery & Design Summit 2014 papers at just £420 (inc. P&P). Simply tick the box on the booking form, send it with payment and your copy will be on its way to you after the meeting. This important manual will be a source of invaluable reference for the future.

About ACI

ACI, a UK owned company, have been running successful conferences for the last 15 years in the USA. Headquartered in Chicago with offices all around the States, they run forums in varied fields and are market leaders in healthcare business conferences. Opening their European head office at the end of 2005, they have expanded rapidly and are launching a series of events covering the maritime, chemicals, healthcare & life sciences, energy and oil & gas industries.

Terms & Conditions

Payment

Payment must be received within five business days of returning the signed contract. After receiving payment a VAT receipt will be issued. If you do not receive a letter outlining details two weeks prior to the event, please contact the Conference Coordinator at ACI Europe Ltd.

Discounts are available for multiple/group bookings. Please call +48 (0) 616 467 022 for more information.

Cancellations

Substitutions are welcome up to 24 hours prior to the event. Cancellations must be received in writing no less than 3 weeks prior to the start of the conference; a full credit voucher towards a future ACI conference will be issued. Any cancellation received less than 3 weeks prior to the start of the event shall be deemed to be a breach of this contract by client, and accordingly, no credits will be given. Cancellations must be received in writing by mail or fax three weeks before the conference. Thereafter the full conference fee is payable. If for any reason ACI Europe Ltd decides to amend, cancel or postpone this conference, the conference fee will not be refunded. Furthermore, ACI Europe Ltd will not be responsible for covering airfare, hotel or other costs incurred by registrants. In the event that ACI Europe Ltd cancel or postpone the event, ACI Europe Ltd reserves the right to transfer this booking to another conference to be held in the following twelve months, or to provide a credit of an equivalent amount to another conference within the following twelve months. The construction, validity and performance of this agreement shall be governed in all respects by the laws of England to the exclusive jurisdiction of whose courts the Parties hereby agree to submit.

Accommodation

The cost of accommodation is not included in the event fee. Preferential rates will be arranged with or near the event venue, and all confirmed delegates will be given details of how to book accommodation at this rate in due course.